百奧賽圖－Ｂ
12 Baoshen South Street
Daxing Bio-Medicine Industry Park Daxing District
Beijing
China
86 10 5696 7680
https://biocytogen.com.cn
版塊: Healthcare
行業: Biotechnology
全職員工: 1,066
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Yuelei Shen Ph.D. | Chairman of the Board, CEO & GM | 2.23M | 無 | 1970 |
| Dr. Jian Ni | Executive Director | 無 | 無 | 1972 |
| Dr. Haichao Zhang | Senior Operation Director of Animal Center & Executive Director | 1.09M | 無 | 1980 |
| Mr. Bin Liu | CFO & Deputy GM | 無 | 無 | 1969 |
| Dr. Yi Yang | Chief Scientific Officer & Deputy GM | 無 | 無 | 1978 |
| Dr. Chaoshe Guo | VP of Marketing & Deputy GM | 無 | 無 | 1971 |
| Ms. Chunli Sun | Director of Human Resources & Supervisor | 無 | 無 | 1980 |
| Ms. Yan Li | Chairman of the Supervisory Committee & Director of the President's Office | 無 | 無 | 1989 |
| Dr. Qingcong Lin | Deputy GM & CEO of Biocytogen Boston Corp. | 無 | 無 | 1965 |
| Mr. Yongliang Wang | Deputy GM, Joint Company Secretary & Chief Secretariat Officer | 無 | 無 | 1985 |
描述
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs in the People's Republic of China, the United States, and internationally. Its core products are YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody, which has completed Phase I clinical trial for the treatment of patients with advanced solid tumors; and YH003, a humanized IgG2 agonistic monoclonal antibody that is in Phase II clinical trial for the treatment of unresectable/metastatic mucosal melanoma and pancreatic duct adenocarcinoma, and Phase I clinical trial for the treatment of solid tumors. The company also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial; YH004, a humanized anti-4- tumor necrosis factor receptor superfamily, member 9 IgG1 antibody that is in Phase I clinical trial for the treatment of advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma; and YH008, an anti-PD-1 x cluster of differentiation 40 (CD40) bispecific antibody that is in Phase I clinical trial for the treatment of solid tumors. In addition, its preclinical candidates include YH012 and YH013, fully human anti-HER2/TROP2 bispecific antibody drugs conjugate for therapeutic product development, manufacturing, and commercialization for all human indications; YH015, a fully human IgG1 antagonistic monoclonal antibody targeting CD40; and YH016 and YH017, two novel molecules. The company has collaboration with Syncromune, Inc.; out license agreement with RemeGen Co., Ltd.; and license agreement with Chipscreen NewWay Biosciences. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was incorporated in 2009 and is headquartered in Beijing, China.
公司管治
截至 無 止，百奧賽圖－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
